Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
Intensity Therapeutics Expands Board, Welcomes New Audit Director
Express News | Intensity Therapeutics Inc - in Connection With Dubin's Appointment, Size of Board Was Increased From Four Directors to Five
Express News | Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
Express News | Intensity Therapeutics-Pursuant to Collaboration Deal, Co to Supply Sakk With Int230-6 as Well as Funding in Amount of up to About $3.0 Mln
Express News | Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Express News | Intensity Therapeutics, Inc. and the Swiss Group for Clinical Cancer Research Sakk Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for Int230-6, Intensity's Lead Drug Candidate
Express News | Intensity Therapeutics Inc - Cash and Investments of $10.5 Mln Expected to Fund Operations Through End of Q1 of 2025
Express News | Intensity Therapeutics Q1 Operating Income USD -4.743 Million
Express News | Intensity Therapeutics Q1 Basic EPS USD -0.34
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer
Intensity Therapeutics | 10-Q: Quarterly report
Express News | Intensity Therapeutics-Got Nasdaq Letter Due to Resignation of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Press Release: Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) Shares
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares Company generated approximately $2.8M of non-dilutive funding to extend cash runway WESTPORT, Conn., March 26, 2024 (GL
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Intensity Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 130.77% Benchmark → $12 Reiterates Speculative Buy → Speculative Buy 11/14/2023 130.77% Benchma
Express News | Intensity Therapeutics Shares Are Are Trading Higher After the Company Reported a Year-over-year Increase in FY24 EPS Results
Intensity Therapeutics Reports FY23 EPS $(1.38) Vs $(2.22) YoY
Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for the same period in 2022. The decrease was primaril
Express News | Intensity Therapeutics 2023 Year-End Cash And Investments $14.8M
No Data